Oncorus had four abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019, which took place from March 29 through April 3, 2019 in Atlanta, GA.
Cancer-killing viruses are specially engineered versions of naturally occurring viruses that are programmed to home in on cancer cells and kill them without harming normal tissues. This is a branch of immuno-oncology that has been overshadowed by more fruitful endeavors, such as the immune checkpoint inhibitors Opdivo (nivolumab) from Bristol-Myers Squibb and Keytruda (pembrolizumab) from Merck, both of which are now certified cancer blockbusters. But several companies are developing cancer-killing viruses, known in the scientific community as “oncolytic” viruses, and some of those efforts are starting to show promise.
The scoop: This startup is pinpointing next-gen oncolytic viruses, which could offer a less expensive, more efficacious immuno-oncology option than cellular therapy, such as autologous CAR-Ts in development. It’s going straight for the hardest-to-treat solid cancers, including a type of brain cancer, glioblastoma multiforme (GBM).
"Newly unveiled Oncorus has raised a $57 million Series A to back its efforts to use next-gen oncolytic viruses to treat aggressive cancers including a type of brain cancer, glioblastoma multiforme (GBM). Active strategic investor Celgene ($CELG) participated in the financing, which was led by MPM Capital."
"The Cambridge, Massachusetts, startup launched on Tuesday announcing that it has raised $57 million in a Series A funding round. Oncorus aims to develop a next-generation immunotherapy platform of oncolytic viruses to treat various kinds of tumors, including highly malignant and aggressive cancers such as glioblastoma multiforme."